Better Buy: Exact Sciences vs. Myriad Genetics
Every industry has companies that qualify as "haves" and others that are "have nots." In genetic testing, Exact Sciences (NASDAQ: EXAS) definitely belongs in the former category this year, with its shares soaring 55%. Myriad Genetics (NASDAQ: MYGN), on the other hand, is more of a "have not" in 2019. The stock is down close to 6% year to date.
But which of these stocks is more likely to be the bigger winner over the long run? Here's what you need to know to choose between Exact Sciences and Myriad Genetics.
Image source: Getty Images.
Source Fool.com
